Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA plus KPD regimen in refractory/relapsed multiple myeloma
ChiCTR2300077932Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tretinoin in multiple myeloma (MM), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Overall response rate. Started Nov 2023; status: recruiting.
02
Drugs
tretinoin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2300077932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077932.